Sanjeeva Reddy

417 total citations
24 papers, 358 citations indexed

About

Sanjeeva Reddy is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Sanjeeva Reddy has authored 24 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Oncology and 7 papers in Organic Chemistry. Recurrent topics in Sanjeeva Reddy's work include Melanoma and MAPK Pathways (10 papers), Synthesis and biological activity (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Sanjeeva Reddy is often cited by papers focused on Melanoma and MAPK Pathways (10 papers), Synthesis and biological activity (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Sanjeeva Reddy collaborates with scholars based in United States and India. Sanjeeva Reddy's co-authors include Ben Tseng, Shailaja Kasibhatla, John Herich, John Drewe, Sui Xiong Cai, Karen Meerovitch, David Y. Bouffard, Henriette Gourdeau, Ling Qiu and Hong Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Sanjeeva Reddy

24 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sanjeeva Reddy United States	6	224	125	77	67	31	24	358
Mina Razzak United Kingdom	9	171 0.8×	129 1.0×	62 0.8×	63 0.9×	26 0.8×	49	397
Annabell F. Leske Australia	6	197 0.9×	160 1.3×	44 0.6×	67 1.0×	43 1.4×	18	379
Jee Sun Yang South Korea	13	153 0.7×	240 1.9×	25 0.3×	78 1.2×	35 1.1×	17	419
Pierre Champelovier France	12	102 0.5×	165 1.3×	34 0.4×	65 1.0×	40 1.3×	17	354
Mairead Young United States	8	148 0.7×	239 1.9×	59 0.8×	86 1.3×	16 0.5×	8	399
Michael Gärtner Germany	9	164 0.7×	306 2.4×	48 0.6×	71 1.1×	38 1.2×	12	505
Hideaki Suna Japan	9	92 0.4×	93 0.7×	47 0.6×	143 2.1×	39 1.3×	11	384
Joshua C. Canzoneri United States	9	143 0.6×	306 2.4×	50 0.6×	96 1.4×	15 0.5×	16	411
Kathleen A. Salvato United States	7	124 0.6×	159 1.3×	88 1.1×	123 1.8×	51 1.6×	10	363
Han-Li Huang Taiwan	12	102 0.5×	277 2.2×	24 0.3×	98 1.5×	42 1.4×	18	387

Countries citing papers authored by Sanjeeva Reddy

Since Specialization

Citations

This map shows the geographic impact of Sanjeeva Reddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanjeeva Reddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanjeeva Reddy more than expected).

Fields of papers citing papers by Sanjeeva Reddy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sanjeeva Reddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanjeeva Reddy. The network helps show where Sanjeeva Reddy may publish in the future.

Co-authorship network of co-authors of Sanjeeva Reddy

This figure shows the co-authorship network connecting the top 25 collaborators of Sanjeeva Reddy. A scholar is included among the top collaborators of Sanjeeva Reddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sanjeeva Reddy. Sanjeeva Reddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reddy, Sanjeeva, et al.. (2022). Development of Cotton stalk harvesting machine for ex-situ application. Ecology Environment and Conservation. 28(8). S61–S66. 1 indexed citations

Smith, Roger A., David J. Zammit, Nitin K. Damle, et al.. (2021). ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models. Molecular Cancer Therapeutics. 20(8). 1327–1337. 19 indexed citations

Thompson, Scott K., Roger A. Smith, Zahra Asgari, et al.. (2021). ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell Reports Medicine. 2(7). 100350–100350. 16 indexed citations

Thompson, Scott K., Roger A. Smith, Zahra Asgari, et al.. (2020). Discovery of Asn007, a Novel Inhibitor of Erk1/2, with a Preferential Activity in RAS- and RAF-Mutant Tumors. SSRN Electronic Journal. 3 indexed citations

Reddy, Sanjeeva, et al.. (2020). Abstract B05: ASN007, an oral ERK1/2 inhibitor, shows strong antitumor activity across a panel of KRAS subtype mutant cancer models. Molecular Cancer Research. 18(5_Supplement). B05–B05. 2 indexed citations

Smith, Roger A., David J. Zammit, & Sanjeeva Reddy. (2018). Abstract B109: ASN004, a novel 5T4-targeted Dolaflexin ADC, causes complete and durable tumor regression in a variety of tumor xenograft models. Molecular Cancer Therapeutics. 17(1_Supplement). B109–B109. 2 indexed citations

Reddy, Sanjeeva, et al.. (2018). Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. Molecular Cancer Therapeutics. 17(1_Supplement). B150–B150. 2 indexed citations

Reddy, Sanjeeva, Niranjan Rao, David J. Zammit, et al.. (2017). Abstract 4204: ASN002: A novel dual SYK/JAK inhibitor with strong antitumor activity in both hematological and solid tumor xenograft models. Cancer Research. 77(13_Supplement). 4204–4204. 5 indexed citations

Rasco, Drew, Ryan J. Sullivan, Nehal J. Lakhani, et al.. (2017). ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). e14102–e14102. 2 indexed citations

10.

García, Jorge A., Robert Dreicer, Allan J. Pantuck, et al.. (2017). Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(6_suppl). 240–240. 1 indexed citations

11.

Thompson, Scott K., Roger A. Smith, Niranjan Rao, Michael J. Wick, & Sanjeeva Reddy. (2017). Abstract 158: ASN003, a highly selective inhibitor of B-Raf and PI3 kinases, shows strong antitumor activity in B-Raf inhibitor resistant patient-derived xenograft models. Cancer Research. 77(13_Supplement). 158–158. 1 indexed citations

12.

Reddy, Sanjeeva, et al.. (2015). Abstract 792: ASN002: A novel dual SYK/JAK inhibitor with strong antitumor activity. Cancer Research. 75(15_Supplement). 792–792. 5 indexed citations

13.

Thompson, Scott K., Mahaboobi Jaleel, Murali Ramachandra, et al.. (2015). Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models. Molecular Cancer Therapeutics. 14(12_Supplement_2). B100–B100. 3 indexed citations

14.

Gatalica, Zoran, et al.. (2015). 213 BRAF mutations are potentially targetable alterations in a wide variety of solid cancers. European Journal of Cancer. 51. S31–S31. 5 indexed citations

15.

Smith, Roger A., Nitin K. Damle, Sanjeeva Reddy, et al.. (2015). Abstract 1693: ASN004, a novel 5T4-targeted Dolaflexin™ antibody drug conjugate, causes complete regression in multiple solid tumor models. Cancer Research. 75(15_Supplement). 1693–1693. 2 indexed citations

16.

Rao, Niranjan, Sanjeeva Reddy, Nitin K. Damle, et al.. (2015). ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies. Blood. 126(23). 4009–4009. 3 indexed citations

17.

Laping, Nicholas J., Sivanandhan Dhanalakshmi, Ramesh Mullangi, et al.. (2013). Abstract C134: EN3356, a novel CYP17A inhibitor for the treatment of castration resistant prostate cancer.. Molecular Cancer Therapeutics. 12(11_Supplement). C134–C134. 1 indexed citations

18.

Levy, Joan, Déborah Braun, Mary DeRome, et al.. (2006). Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Cancer Research. 66. 213–214. 25 indexed citations

19.

Kasibhatla, Shailaja, Henriette Gourdeau, Karen Meerovitch, et al.. (2004). Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity. Molecular Cancer Therapeutics. 3(11). 1365–1374. 175 indexed citations

20.

Cai, Sui Xiong, Bao Nguyen, Shaojuan Jia, et al.. (2003). Discovery of Substituted N-Phenyl Nicotinamides as Potent Inducers of Apoptosis Using a Cell- and Caspase-Based High Throughput Screening Assay. Journal of Medicinal Chemistry. 46(12). 2474–2481. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact